Secreted Left Atrial P-Selectin in Mitral Stenosis after PBMV: When to Measure

M. Saifur Rohman

The glycoprotein P-selectin, a membrane component of cell storage granules, is rapidly translocated from α-granules of platelets and the Weibel–Palade bodies of endothelial cells to the cell surface following an inflammatory process or other stimulations. P-selectin is a cell adhesion molecule of activated platelets and endothelial cells of interest because of its role in modulating interactions between blood cells and the endothelium, and also because of the possible use of its soluble form in plasma as a predictor of adverse cardiovascular events.1

In endothelial cells, within minutes of its stimulation in vitro by inflammatory mediators, such as histamine, thrombin, or phorbol esters, or hypoxia, Weibel–Palade bodies are mobilized and their von Willebrand factor is degranulated. At the same time, P-selectin is also expressed at the surface as quick as two minutes after stimulation. However, this expression is short-lived, reaching its peak after only 10 minutes, declining back to baseline levels after 3 hours. Additional synthesis of P-selectin is brought about within 2 hours by cytokines, such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), and by thrombin, lipopolysaccharide or oxygen radicals. Immunofluorescence and confocal laser cytometry are usually used to measure the translocation upon this activation.1

As P-selectin is originally defined on activated platelets and they are easier to obtain and study, there are considerably more data from platelet compared to endothelial ones. There are approximately 10,000 P-selectin molecules on the surface of an activated platelet, translating to a density of perhaps 350 sites/μm², a density that exceeds even those on athrombin or histamine-stimulated endothelial cell in vitro by an approximate factor of ten.1 In this case, flow cytometry of activated platelet and microparticles was used to measure P-selectin.

The development of monoclonal antibody-based assay procedure (enzyme-linked immunosorbent assay (ELISA)) has allowed the quantification of P-selectin in fluids. The first commonly-asked question is: what is exactly being measured? This point has arisen from the discovery of messenger RNA/cDNA coding for different variants of P-selectin, some of which coded for a molecule lacking a transmembrane portion, implying direct 'secretion' from the cell. It soon follows that the increased presence of a truncated soluble P-selectin isoform in plasma might reflect an increase in the activity of this form of message. Alternative mechanisms for the appearance of soluble P-selectin include simple shedding or active cleavage from cell surface, presumably by a non-specific enzyme or other mediator(s) that may arise from leukocytes, endothelium, or elsewhere. The second question often asked is: where does the P-selectin come from?
As P-selectin is present within both endothelial cells and the platelets, there has been considerable debate whether or not raised plasma levels of P-selectin reflects endothelial dysfunction, platelet activation, or both. Overall, there are too few serious data to contradict the proposition that raised soluble P-selectin reflects platelet disturbance. Therefore, a soluble form of it, detectable by ELISA, may present in the blood mainly because of increased platelet activation. Since soluble P-selectin is produced not only by endothelial cells but also, even mainly, by platelets, all factors affecting platelet activation should also be considered as major contributors, in spite of production of endothelial P-selectin related to hemodynamic changes or reduced shear stress after percutaneous transvenous Balloon Mitral Valvulotomy (PBMV).

As mentioned, when soluble P-selectin is measured, confounding factors affecting P-selectin level should also be considered, such as previous treatment using calcium channel inhibitor, statin, anticoagulant and/or antiplatelet. Cessation of smoking is also known to reduce soluble P-selectin. In mitral stenosis (MS), although there is a significant increase in mitral valve area and significant decrease in mean left atrial and pulmonary arterial pressures immediately after PBMV, there were no significant immediate (10 minutes after PBMV) changes found in plasma atrial P-selectin. Therefore, persistent increase in plasma P-selectin levels after PBMV might be partly attributed to the persistent endothelial dysfunction after PBMV. Plasma soluble P-selectin levels could not reflect changes in individual platelets, and there is an absence of significant correlations between the plasma levels of soluble P-selectin in the left atrium and left atrial volume index, all of which reported by Shanti et al, who used 20 samples with wide variant of soluble P-selectin level from ELISA that resulted in big standard deviation. Similar results were also shown by Chen et al using the same sample size. However, previous studies with a larger sample size have shown significant decrease of left atrial P-selectin level at 24 hour, and 4 weeks after PBMV with no significant difference between peripheral and left atrial P-selectin. Hasan-Ali et al. showed that P-selectin change correlated with the change in left atrial diameter and pulmonary artery systolic pressure after 2 weeks of PBMV procedure in 65 patients. It may take a longer period of altered hemodynamic to reduce left atrial soluble P-selectin in MS patients following PBMV.

Taken together, many factors affected the change of left atrial soluble P-selectin level after PBMV, such as its baseline level, the effect of drugs affecting P-selectin expression and the duration of measurement from PBMV procedure.

References